Form 4: Biodesix Inc. Chief Accounting Officer Reports Stock Transactions
SEC Form 4 Filing
Chris Vazquez, Chief Accounting Officer of Biodesix Inc., reports the vesting and sale of common stock to cover taxes, along with adjustments to restricted stock units.
Summary
- On February 10, 2025, Chris Vazquez, the Chief Accounting Officer of Biodesix Inc., had 9,666 shares of common stock acquired through the vesting of restricted stock units (RSUs).
- Vazquez also sold 3,630 shares of common stock on February 11, 2025, at a weighted average price of $0.9242 per share to cover taxes upon the vesting of RSUs.
- Following these transactions, Vazquez directly owns 17,623 shares of Biodesix Inc.
- The transactions also involved adjustments to the number of restricted stock units beneficially owned, with 601, 4,694 and 4,371 RSUs vesting on February 10, 2025.
- These RSUs vest in quarterly or annual installments from February 8, 2022, February 8, 2023 and January 15, 2024, respectively, contingent upon continued service with the Issuer.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about insider trading activity.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's stock. It's common for executives to receive stock options or restricted stock units as part of their compensation, and their trading activity is closely monitored.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies and their executives.
- The vesting schedules and tax-related sales are typical components of executive compensation packages.
- Comparable companies in the biotech or diagnostics space would have similar insider transaction reporting.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the sale of shares in the market.
- Employees who also had RSUs vesting at the same time may be impacted similarly.
Key Dates
| Date | Description |
|---|---|
| 02/08/2022 | Start date for vesting of some restricted stock units in a series of sixteen successive quarterly installments. |
| 02/08/2023 | Start date for vesting of some restricted stock units in a series of four successive equal annual installments. |
| 01/15/2024 | Start date for vesting of some restricted stock units in a series of four successive equal annual installments. |
| 02/10/2025 | Date of earliest transaction: acquisition of common stock through RSU vesting and vesting of RSUs. |
| 02/11/2025 | Date of sale of common stock to cover taxes upon RSU vesting. |
| 02/12/2025 | Date of signature for the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.